SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bob L who wrote (1654)4/19/1999 10:04:00 AM
From: scaram(o)uche  Read Replies (1) of 1762
 
Bob:

Sometime soon (I promise), I'm going to cruise through the excerpts that you posted about a month ago. Just wanted to point at this as a reminder and emphasize that we really need to know if tickling the cell surface with anti-CD20 really does have an indirect impact on the efficacy of CHOP........

Investigators Report Genta's Antisense Drug Combined With Standard Chemotherapy Cures Human Lymphomas
and Breast Cancers in Mouse Models



Results with G3139 Support Ongoing Clinical Program

LEXINGTON, Mass., April 19 /PRNewswire/ -- Genta Incorporated
(Nasdaq: GNTA) announced that scientists reported the results of preclinical
studies with Genta's lead product in development, G3139, at the recently
concluded 90th annual meeting of the American Association for Cancer Research
(AACR) held in Philadelphia, Pa.
G3139 was designed to reduce the Bcl-2 protein level in cancer through an
"antisense" mechanism that specifically targets the bcl-2 gene product. In
several human cancers, the protein produced by the bcl-2 gene is believed to
be a major factor in resistance to treatment with many anticancer drugs. (snip)

In the interim, of course, we've learned that the cold antibody trial will be a part of the CLTR NDA submission. Thanks again for your efforts.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News